Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity

Archives of Neurology

Volumn 62, Issue 9, 2005, Pages 1371-1376

  Bermel, Robert A ^a,b   Puli, Srinivas R ^a,b   Rudick, Richard A ^c   Weinstock Guttman, Bianca ^a,b   Fisher, Elizabeth ^c   Munschauer III, Frederick E ^a,b,d   Bakshi, Rohit ^a,b,e,f  

^a UNIVERSITY AT BUFFALO   (United States)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Physicians Imaging Centers   (United States)

^e Center for Neurological Imaging Partners Multiple Sclerosis Center   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM;

ADULT; ARTICLE; BRAIN ATROPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; GRAY MATTER; HUMAN; IMAGE ENHANCEMENT; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARENCHYMA; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; BRAIN DISEASES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; FEMALE; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS;

EID: 25144486613     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.9.1371     Document Type: Article

References (53)

1. Rudick RA, Fisher E, Lee JC, et al; Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology. 1999;53:1698-1704.
2. Bakshi R, Minagar A, Jaisani Z, Wolinsky JS. Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx. 2005;2:277-303.
3. Bermel RA, Innus MD, Tjoa CW, Bakshi R. Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study. Neuroreport. 2003;14:335-339.
4. Chard DT, Griffin CM, Parker GJ, et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain. 2002;125:327-337.
5. Bakshi R, Miletich RS, Kinkel PR, et al. High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging. 1998;8:228-234.
6. Sharma R, Narayana PA, Wolinsky JS. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult Scler. 2001;7:221-226.
7. Cifelli A, Arridge M, Jezzard P, et al. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol. 2002;52:650-653.
8. Bakshi R, Ariyaratana S, Benedict RHB, Jacobs L. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch Neurol. 2001;58:742-748.
9. Kidd D, Barkhof F, McConnell R, et al. Cortical lesions in multiple sclerosis. Brain. 1999;122:17-26.
10. Simon JH, Kinkel RP, Jacobs L, et al. A Wallerian degeneration pattern in patients at risk for MS. Neurology. 2000;54:1155-1160.
11. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278-285.
12. Meier DS, Weiner HL, Khoury SJ, Guttmann CR. Magnetic resonance imaging surrogates of multiple sclerosis pathology and their relationship to central nervous system atrophy. J Neuroimaging. 2004;14(suppl 3):46S-53S.
13. Zivadinov R, Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging. 2004;14(suppl 3):27S-35S.
14. Benedict RHB, Carone DA, Bakshi R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J Neuroimaging. 2004;14(suppl 3):36S-45S.
15. Fisher E, Rudick RA, Simon JS, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59:1412-1420.
16. Bermel RA, Sharma J, Tjoa CW, et al. A semiquantitative measure of whole-brain atrophy in multiple sclerosis. J Neurol Sci. 2003;208:57-65.
17. Christodoulou C, Krupp LB, Liang Z, et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. Neurology. 2003;60:1793-1798.
18. Bermel RA, Bakshi R, Tjoa CW, et al. Bicaudate ratio as an MRI marker of brain atrophy in multiple sclerosis. Arch Neurol. 2002;59:275-280.
19. Benedict RHB, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol. 2004;61:226-230.
20. Zivadinov R, Sepcic J, Nasuelli D. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;70:773-780.
21. Rudick RA. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging. 2004;14(suppl 3):54S-64S.
22. Sormani MP, Rovaris M, Valsasina P, Wolinsky JS, Comi G, Filippi M. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology. 2004;62:1432-1434.
23. Frank JA, Richert N, Bash C, et al. Interferon-β-1b slows progression of atrophy in RRMS: three-year follow-up in NAb- and NAb+ patients. Neurology. 2004;62:719-725.
24. Jones CK, Riddehough A, Li DKB, et al; PRISMS Study Group, UBC MS/MRI Research Group. MRI cerebral atrophy in relapsing-remitting MS: results from the PRISMS trial [abstract]. Neurology. 2001;56(suppl 3):A379.
25. Minagar A, Toledo EG, Alexander JS, Kelley RE. Pathogenesis of brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging. 2004;14(suppl 3):5S-10S.
26. Drayer B, Burger P, Hurwitz B, et al. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content? AJR Am J Roentgenol. 1987;149:357-363.
27. Bakshi R, Shaikh ZA, Janardhan V. MRI T2 shortening ("black T2") in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport. 2000;11:15-21.
28. Bakshi R, Benedict RH, Bermel RA, et al. T2 hypointensity in the deep gray matter of MS patients: a quantitative magnetic resonance imaging study. Arch Neurol. 2002;59:62-68.
29. Bakshi R, Dmochowski J, Shaikh ZA, Jacobs L. Gray matter T2 hypointensity is related to plaques and atrophy in brains of multiple sclerosis patients. J Neurol Sci. 2001;185:19-26.
30. Nishii T, Hirata A, Masaki T, et al. Reduced signal intensity of T2 weighted MR imaging of thalamus and putamen in multiple sclerosis in Japan [in Japanese]. Rinsho Shinkeigaku. 2000;40:677-682.
31. Schenck JF, Zimmerman EA. High-field magnetic resonance imaging of brain iron: birth of a biomarker? NMR Biomed. 2004;17:433-445.
32. LeVine SM. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res. 1997;760:298-303.
33. Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain. 2002;125:1462-1473.
34. Craelius W, Migdal MW, Luessenhop CP, et al. Iron deposits surrounding multiple sclerosis plaques. Arch Pathol Lab Med. 1982;106:397-399.
35. Adams CW. Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1988;51:260-265.
36. Kotze MJ, de Villiers JN, Rooney RN, et al. Analysis of the NRAMP1 gene implicated in iron transport: association with multiple sclerosis and age effects. Blood Cells Mol Dis. 2001;27:44-53.
37. LeVine SM, Lynch SG, Ou CN, et al. Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. Brain Res. 1999;821:511-515.
38. Jacobs LD, Cookfair DL, Rudick RA, et al; Multiple Sclerosis Collaborative Research Group (MSCRG). A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Mult Scler. 1995;1:118-135.
39. Jacobs LD, Cookfair DL, Rudick RA, et al; The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285-294.
40. Simon JH, Jacobs LD, Campion M, et al; The Multiple Sclerosis Collaborative Research Group. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol. 1998;43:79-87.
41. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
42. Vymazal J, Righini A, Brooks RA. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology. 1999;211:489-495.
43. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5:143-156.
44. Simon JH, Lull J, Jacobs LD, et al; Multiple Sclerosis Collaborative Research Group. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Neurology. 2000;55:185-192.
45. Mehindate K, Sahlas DJ, Frankel D, et al. Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J Neurochem. 2001;77:1386-1395.
46. Minagar A, Long A, Ma T, et al. Interferon (IFN)-beta1a and IFN-beta1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier. Endothelium. 2003;10:299-307.
47. Fabiano AJ, Sharma J, Weinstock-Guttman B, et al. Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study. J Neuroimaging. 2003;13:307-314.
48. Filippi M, Rocca MA, Colombo B, et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage. 2002;15:559-567.
49. Fabiano AJ, Horsfield MA, Bakshi R. Interhemispheric asymmetry of brain diffusivity in normal individuals: a diffusion-weighted MR imaging study. AJNR Am J Neuroradiol. 2005;26:1089-1094.
50. Sherman SM, Guillery RW. Exploring the Thalamus. San Diego, Calif: Academic Press; 2001:5-18.
51. Rudick RA, Fisher E, Lee JC, et al. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler. 2000;6:365-372.
52. Double KL, Maywald M, Schmittel M, Riederer P, Gerlach M. In vitro studies of ferritin iron release and neurotoxicity. J Neurochem. 1998;70:2492-2499.
53. Levine SM, Chakrabarty A. The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann N Y Acad Sci. 2004;1012:252-266.